Real-world evaluation shows teplizumab improves glycaemic control in type 1 diabetes, suggesting potential biomarkers for early intervention.
Teplizumab can be safely and effectively administered in clinical practice. Early glycaemic improvements and reductions in CD4 preproinsulin-specific TCRs suggest that post-treatment immunological changes may serve as biomarkers to guide early-stage intervention.
No takes yet. Share an insight, caveat, or question.
Karakus et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: